[High-dose progestational contraception: side effects]

Progestational contraception (CMP) is rarely used. In France, its indications are not clearly defined. The prescription is justified when there is a contra-indication to estrogen use (uterus fibroids, endometrial hyperplasia, endometriosis, fibro-cystic disease of the breast). The side effects are menstruation disorders (metrorrhagias, amenorrhea), weight gain, atherogenic metabolic changes. Actually, nor-pregnane derivatives, which correctly block ovulation, do not seem to have a deleterious effect on glucide and lipid parameters. At last, it is not sure that CMP may be prescribed to a patient previously treated for a breast cancer.